UNSPSC 85816026: Introduction of immunosuppressive into peripheral artery, open approach

This classification denotes the group of activities that yields a administrative intervention or procedure to introduction of immunosuppressive into peripheral artery, open approach. This administrative intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 3E050WL

UNSPSC 85816026 Introduction of immunosuppressive into peripheral artery, open approach is a Commodity code that shows little relevant recent activity aligned with its nominal clinical scope. The recent opportunities tagged under this code span telehealth urgent care, PACE operations, occupational health services, cancer screening, youth crisis stabilization, and other behavioral health and general medical services—none of which involve peripheral artery intervention or immunosuppressive drug administration. The mismatch suggests either consistent miscoding at the point of solicitation or that the code sits dormant in active state and local procurement while issuing bodies apply it to unrelated health services.

State and local health authorities—California's Inland Empire Health Plan, Nevada's Health Authority, Ventura County Behavioral Health, San Mateo County, Fairfax County, Solano County, and others—are the primary buyers across recent postings. Activity concentrates in California, Nevada, Colorado, Georgia, Florida, Kansas, and Washington. The largest recent procurement is Nevada Health Authority's RFP for Program of All Inclusive Care for the Elderly (PACE), with proposals due December 10, 2026, spanning three service areas with fixed monthly capitation rates ranging from $4,532.24 to $8,804.32 per participant. Inland Empire Health Plan issued an RFI for 24/7 virtual urgent care services due October 31, 2026, and DeKalb County, Georgia solicited medical services with a November 12, 2026 proposal deadline. Unless your firm has specialized expertise in peripheral arterial immunosuppressive delivery—a rare clinical procedure unlikely to anchor state and local procurement volume—pursuit under this code is not warranted.